β-Cell cycle progression and proliferation are critical to maintain β-cell mass in adult mice. Of the cell cycle inhibitors, p27Kip1 is thought to be the primary modulator of the proliferative status in most cell types. p27 plays a role in β-cell adaptation in genetic models of insulin resistance. To study the role of p27 in β-cells during physiological conditions and at different stages of β-cell differentiation, we studied mice deficient of or overexpressing p27. Experiments in p27-deficient mice showed improved glucose tolerance and hyperinsulinemia. These changes were associated with increased islet mass and proliferation. The experiments overexpressing p27 in β-cells were performed using a doxycycline-inducible model. Interestingly, overexpression of p27 for 16 weeks in β-cells from adult mice had no effect on glucose tolerance, β-cell mass, or proliferation. In contrast, induction of p27 expression during β-cell development or early neonatal period resulted in severe glucose intolerance and reduced β-cell mass by decreased proliferation. These changes were reversible upon discontinuation of doxycycline. These experiments suggest that p27 is a critical molecule for β-cell proliferation during β-cell development and early postnatal life but not for maintenance of adult mass.

The steps controlling entry and progression through G1 are dependent on cell type and context. Little is known about the cell cycle in β-cells, but recent work from several laboratories has shown that cyclin-dependent kinase-4 (cdk4) and cyclins D1 and D2 are critical regulators of β-cell proliferation and maintenance of β-cell mass after birth (14). Moreover, overexpression of cdk4 by adenoviral transfer in human islets increase proliferation in vitro (5). All these findings suggest that modulation of cyclin D–cdk4 complex activity is a major step in cell cycle progression, proliferation, and maintenance of β-cells (rev. in 6). Entry and progression through the cell cycle is negatively regulated by cell cycle inhibitors (CKIs). The regulation of β-cell cycle and the importance of the different CKIs during development, early postnatal period, and maintenance of β-cell mass has not been completely elucidated.

Two types of CKIs have been described. The inhibitor of kinase 4 (INK4) CKIs (p16INK4a, p15INK4b, p18INK4c, and p19INK4d) inhibit kinase activity of Cdk4–6/cyclin D complexes. The second family of CKIs, Cip/Kip (p21Cip1, p27Kip1, and p57Kip2), inhibits primarily Cdk2 but have some assembling functions on the cdk4/cyclin D complex. Of the CKIs, p27Kip1 is thought to be the primary modulator of the proliferative status in most cell types, where it functions to induce and maintain the quiescent state. The serine-threonine kinase Akt, a major regulator of β-cell proliferation, has been shown to regulate p27 levels by transcriptional and posttranslational mechanisms in other cell models (711). Recent experiments have shown that p27Kip1 progressively accumulates in the nucleus of pancreatic β-cells in genetic models of insulin resistance (12), and deletion of p27Kip1 ameliorated hyperglycemia in these animal models of type 2 diabetes (12). Moreover, overexpression of p27 under the insulin promoter induces diabetes (12). These experiments suggest that p27 is critical to maintain β-cell replication and can contribute to the pathogenesis of type 2 diabetes. While these experiments clearly indicate the importance of p27 in regulation of β-cell mass, it is entirely unclear whether the inhibition of β-cell cycle by this CKI mainly occurs during development or postnatally.

The current studies extend the observation by Uchida et al. (12) by studying the role of p27 in regulation of β-cell mass under physiological conditions and by overexpressing p27 in β-cells during development, early postnatal life, and adult stages using a doxycycline-inducible system. Surprisingly, overexpression of this CKI in β-cells from adult mice did not alter glucose tolerance, β-cell mass, or proliferation. In contrast, overexpression of p27 during β-cell development and/or the early postnatal period resulted in severe glucose intolerance, reduced β-cell mass, and proliferation; these abnormalities were reversed after discontinuation of doxycycline treatment. Taken together, the results of these experiments indicate that p27 has differential effects in regulation of β-cell mass during development, neonatal period, and adult life.

p27Kip1-deficient mice are in C57/B6 background and have been described previously (13). Experiments were performed in 3- to 4-month-old female mice. RIP7-rtTA mice express the reverse-tetracycline transactivator under the control of the rat insulin II gene and are in C57Bl/6 (B6)/CBA mice (14). These mice were kindly provided by Gerhard Christofori and Shimon Efrat. The tetOp27Kip mice have been previously described and contain p27 under the regulation of tetracycline-responsive element. RIP7-rtTA/tetOp27Kip mice (DT) were obtained by crossing hemizygous RIP7-rtTA with hemizygous tetOp27Kip mice. Control and experimental animals were on comparably mixed background. All procedures were performed in accordance with the Washington University Animal Studies Committee.

Doxycycline administration.

The studies performed to determine the role of p27 in β-cells from adult mice were performed in 8-week-old male mice. Mice on doxycycline treatment were given 2 mg/ml doxycycline in a 5% sucrose solution instead of drinking water for 18 weeks. To overexpress p27 during development, slow-release doxycycline pellets (60-day release; 0.7 mg doxycycline per day) (Innovative Research of America, Sarasota, FL) were implanted subcutaneously using a trochar as described by the manufacturer. Females were administered doxycycline pellets before mating so that the transgenic offspring were exposed to the drug in utero. Induction of p27 in the early neonatal period was achieved by adding doxycycline to the drinking water after birth. To induce p27 in the neonatal period only, doxycycline in the drinking water was administered to neonates from females that did not have the doxycycline pellet implanted. The same proportion of males and females were included in each experimental group.

Islet isolation and immunoblotting from isolated islets.

Islet isolation was accomplished by collagenase digestion as described previously (15). After isolation, islets were handpicked and lysed in lysis buffer. The following antibodies were used: p27 (Cell Signaling, Beverly, MA) and α-tubulin (Sigma, St. Louis, MO). Protein obtained from islets from RIP7-rtTA/tetOp27Kip mice (DT) and single transgenic (ST) mice, (50 μg) (∼100 islets) on chronic doxycycline treatment were used for each experiment. Membranes containing islet lysates were incubated for 24 h with primary antibodies at the dilutions recommended by the manufacturer. Immunoblotting experiments were performed at least three times in duplicate.

Immunohistochemistry and immunofluorescence.

Pancreatic tissue was fixed overnight in 3.7% formalin solution and embedded in paraffin using standard techniques. Immunohistochemistry for insulin (Sigma), bromodeoxyuridine (BrdU) (Amersham, Piscataway, NJ), Ki67 (Novocastra, Burlingame, CA), and p27 (Cell Signaling) was performed in 5-μm sections. Assessment of apoptosis was performed by immunofluorescence using cleaved caspase 3 antibodies (Cell Signaling) using the dilution recommended by the manufacturer.

Islet morphometry and proliferation analysis.

β-Cell mass was calculated by point-counting morphometry from five insulin-stained sections (4 μm) separated by 200 μm using the BQ Classic98 MR software package (Bioquant, Nashville, TN) as described previously (16). Proliferation was assessed in insulin- and BrdU-stained sections from p27-deficient mice injected with BrdU for 6 h as previously described (15). Insulin- and Ki67-stained (Novocastra) sections were also used to assess proliferative rate when indicated. At least 2,000 insulin-stained cells were counted for each animal. To calculate the mean size of the individual β-cells, the β-cell area was divided by the number of β-cell nuclei in the covered area. The β-cell size measurements were performed in at least 100 islets from insulin-stained sections.

Metabolic studies.

Fasting blood samples were obtained from the tail vein after overnight or 6 h fasting as indicated in the corresponding figure legend. Glucose was measured on whole blood using AccuChek II glucometer (Roche Diagnostics, Indianapolis, IN). Plasma insulin levels were determined using a rat insulin enzyme-linked immunosorbent assay kit (Linco, St. Louis, MO). Glucose tolerance tests were performed in 18-h fasted animals by injecting glucose (2 mg/g i.p.) as described previously (15). Insulin tolerance tests were done in 4-h fasted mice followed by glucose measurements at 30, 60, and 120 min after intraperitoneal insulin injection using 0.75 units/kg.

Statistical analysis.

All values are expressed as means ± SE. Paired Student’s t test was used for all other comparisons. Differences were considered statistically significant at a P value <0.05.

p27kip-deficient mice exhibit improved glucose tolerance.

To begin to elucidate the role of endogenous p27kip in glucose homeostasis, we used p27-deficient mice (p27−/−) (13). As previously described, p27−/− mice were heavier compared with heterozygous or wild-type controls (Fig. 1A). Blood glucose levels after 6 h fasting were significantly lower in 3-month-old p27−/− mice (Fig. 1B). The decreased glucose level in p27−/− mice was associated with hyperinsulinemia in 6-h fasted mice (Fig. 1C). To determine glucose homeostasis after a glucose challenge, we performed an intraperitoneal glucose tolerance test (Fig. 1C). No difference in glucose levels was observed after an overnight fast (Fig. 1D). Blood glucose in p27−/− mice was significantly reduced at 30 and 60 min after glucose injections (P < 0.05; Fig. 1D). The results of these experiments suggest that p27 deficiency results in increased weight and improved glucose tolerance.

Deletion of p27kip increases islet mass and proliferation.

Knowing that insulin tolerance tests in p27−/− mice were unaltered (data not shown), we reasoned that the hyperinsulinemia observed could result from alterations in β-cell mass. Islet mass was augmented by twofold in p27−/− mice compared with wild-type mice (Fig. 2A). The size of individual β-cells was not altered in p27−/− mice (data not shown). To determine whether the alteration in β-cell mass results from increased proliferation, we assessed the rate of BrdU incorporation in p27-deficient mice and controls. The proliferative rate observed in p27−/− mice was increased compared with that of wild-type mice (P < 0.05; Fig. 2B). These results indicate that p27 may function as a negative regulator of β-cell proliferation. However, it is unclear whether the effect of p27 occurs during development or postnatally.

Overexpression of p27 in β-cells from adult mice using a doxycycline-inducible system has no effect on glucose tolerance or β-cell mass.

Overexpression of p27 using the rat insulin promoter induces diabetes (12). To determine the importance of p27 in regulation of β-cell proliferation during the different stages required to achieve adult β-cell mass, we used a doxycycline-inducible system. These mice were generated by crossing mice expressing the tetracycline reverse transactivator under the control of the rat insulin promoter (RIP-rTTA) with mice expressing p27 under the control of the tetracycline operator (tetOp27) (DT). The control group included mice containing one of the transgenes (ST). The mice with one of the transgenes (RIP-rTTA or tetOp27) were combined for the analysis since no difference in glucose homeostasis or weight was observed between the groups. The metabolic phenotype of the ST was similar to the wild-type mice (data not shown). To induce p27 in β-cells from adult mice, 8-week-old mice were given doxycycline in their drinking water for 18 weeks. Immunoblotting for p27 in islets from mice chronically receiving doxycycline showed a two-band pattern representing the phosphorylated and nonphosphorylated forms of p27 as described (12) (Fig. 3A). p27 expression was increased by 2.8-fold in islets from DT mice chronically receiving doxycycline (Fig. 3B). These results were confirmed by immunostaining for p27 in pancreatic sections from mice after 18 weeks on doxycycline (data not shown).

To begin to elucidate the metabolic phenotype of these mice, we first measured glucose and insulin levels at different time points during doxycycline treatment. Similar weight gain was observed in all groups after doxycycline treatment (data not shown). Glucose levels in DT mice during the doxycycline treatment were not different than those obtained from ST mice (Fig. 3C). Serum concentration of insulin was similar in DT and ST mice during the experiment (Fig. 3D). Complementary assessment of carbohydrate metabolism was performed by glucose tolerance tests. Glucose tolerance tests before and 6, 12, and 16 weeks after (data not shown for 6 and 12 weeks) doxycycline treatment were similar among the groups (Fig. 3E and F). Taken together, these experiments suggest that overexpression of p27 in β-cells from adult mice has no effect on carbohydrate metabolism.

Significant reductions on β-cell mass should be achieved before detecting glucose intolerance. To determine whether the lack of metabolic changes were associated with alterations in islet morphology, we measured β-cell mass and proliferation (Fig. 4). Islet mass showed no difference in the DT mice compared with ST mice (Fig. 4A). The size of individual β-cells, estimated by measurement of β-cell area, was not affected (data not shown). The examination of the β-cell proliferation by BrdU staining in DT mice after 18 weeks of doxycycline treatment was no different than that of ST mice (Fig. 4B). These results indicate that overexpression of p27 in the adult β-cell does not alter β-cell mass and proliferation.

Overexpression of p27 in β-cells during embryonic stages and postnatally induces diabetes.

Based on the lack of phenotype found in our experiments and the severe diabetes observed by overexpressing p27 in β-cells using the insulin promoter (12), we hypothesized that p27 could play a more important role during development and/or the early postnatal period. To test this, we assessed the effect of p27 overexpression by doxycycline treatment during pregnancy and after birth. This was achieved by implanting doxycycline pellets subcutaneously in nonpregnant females before mating, followed by doxycycline in the water after the pups were born. Interestingly, 3-week-old DT mice showed significant hyperglycemia and hypoinsulinemia after 6 h of fasting (Fig. 5A and B). Glucose tolerance tests in 4-week-old mice demonstrated that DT mice were hyperglycemic at 30 and 60 min after glucose injections compared with ST mice (P < 0.05; Fig. 5C). The hyperglycemic phenotype was more severe at 8 weeks of doxycycline treatment (P < 0.05; Fig. 5C). Insulin sensitivity assessed by insulin tolerance tests was not different between DT mice and controls (data not shown). As shown in Fig. 5E and F, the hyperglycemic phenotype observed in DT mice resulted from reduced β-cell mass and decreased proliferation. Assessment of apoptosis by cleaved caspase 3 staining demonstrated that apoptotic rate was similar in DT and control mice (data not shown). These studies suggest the phenotype of mice overexpressing p27 during β-cell development and early postnatal life is a more severe phenotype than that observed after overexpression of β-cells from adult mice. These data also indicate that p27 plays a more important role during proliferative conditions such as those observed in development and the early postnatal period.

Induction of p27 postnatally results in glucose intolerance.

To determine the role of p27 in β-cell proliferation during the early postnatal period and the contribution of this stage to the hyperglycemic phenotype described above, we administered doxycycline to newborn mice. After 6 h of fasting, 3-week-old DT mice exhibited higher glucose levels compared with ST mice (P < 0.05; Fig. 6A). Glucose tolerance tests performed in 3-week-old mice showed that glucose levels in DT mice were significantly higher at 30 and 60 min after glucose injections (Fig. 6B). After 8 weeks of age, DT mice exhibited severe hyperglycemia at 30, 60, and 120 min after glucose injections, suggesting that the severity of the phenotype is progressive (Fig. 6C). The results of these experiments suggest that p27 is an important regulator of β-cell cycle during the proliferative wave in the early postnatal period.

Glucose intolerance and alterations in β-cell mass by overexpression of p27 in β-cells during development and early postnatal period are reversible.

To determine whether the metabolic and/or the β-cell mass phenotype was reversible, we followed mice after discontinuation of doxycycline treatment. For these studies, DT and ST mice were treated with doxycycline during development and postnatally for 4 weeks. At this time, doxycycline treatment was discontinued in half of the DT mice and all the experimental groups followed for 4 more weeks. As shown previously, DT mice treated with doxycycline during β-cell development and 4 weeks after birth exhibited fasting hyperglycemia and glucose intolerance assessed by intraperitoneal glucose tolerance tests (Fig. 7A and B). Compared with ST mice, glucose values after 6 h fasting were higher in DT mice with doxycycline and DT mice in which doxycycline was discontinued for 2 weeks (Fig. 7C). In contrast to the glucose tolerance results observed before discontinuation of doxycycline treatment, DT mice that were not receiving doxycycline for 2 weeks showed significant hyperglycemia only at 30 min after glucose load (Fig. 7D). Three weeks after discontinuation of doxycycline, fasting glucose in DT mice was similar to that of ST mice (Fig. 7E). Glucose tolerance in DT mice, in which doxycycline was discontinued for 3 weeks, showed almost complete recovery of hyperglycemia (Fig. 7F). Fasting glucose and glucose tolerance in DT mice that were off doxycycline for 4 weeks were not different compared with that of ST control mice (Fig. 7G and H). These data suggest that the abnormalities in carbohydrate metabolism induced by overexpression of p27 during β-cell development and postnatally are reversible.

To determine whether the correction of glucose intolerance after removal of doxycycline treatment resulted from recovery of β-cell mass, we performed islet morphometry in the mice used in Fig. 7. Mice treated with doxycycline exhibited reduced β-cell mass, confirming the results showed in Fig. 5E. More importantly, DT mice in which doxycycline treatment was discontinued for 4 weeks exhibited β-cell mass, which was comparable to that of controls (Fig. 7A). The assessment of β-cell proliferation showed that the proliferative rate in mice that received doxycycline throughout the experiment was lower than that of control ST mice (Fig. 8). Our findings imply that the proliferative rate in DT mice, which did not received doxycycline for the last 4 weeks of the experiment, was intermediate but not statistically different than that of the ST controls or DT mice treated with doxycycline (Fig. 8). These experiments suggest that the rapid improvement of the metabolic phenotype results from restoration of β-cell mass.

The result of the current studies assessed the role of p27 in the regulation of β-cell mass by using p27-null mice and doxycycline-inducible mice overexpressing p27 in β-cells. The present work shows that p27 deficiency results in increased β-cell proliferation and mass and improved glucose tolerance. Doxycycline-induced overexpression of p27 in β-cells from adult mice showed normal glucose tolerance and comparable β-cell mass and proliferation. In contrast, overexpression of p27 during β-cell development and the first 4 weeks of postnatal life resulted in glucose intolerance and decreased β-cell mass and proliferation. This same phenotype was also observed by overexpressing p27 only after birth, suggesting that p27 is critical in determining adult β-cell mass. Taken together, these studies suggest that p27 is a major determinant for β-cell cycle and mass and that the major effect of this CKI occurs during β-cell development and the early wave of proliferation that occurs during the first month of life. This work also implies that p27 could be a critical regulatory molecule under conditions that require β-cell expansion, such as adaptation to insulin resistance.

Recent data from several laboratories suggest that modulation of the cyclin D–cdk4 complex activity is a major step that controls cell cycle progression, proliferation, and maintenance of β-cell mass (14). Moreover, overexpression of cdk4 by adenoviral transfer in human islets increases proliferation in vitro (5). The cell cycle is negatively regulated by two families of CKIs. The INK4 CKIs, p16INK4a, p15INK5b, and p19INK4d, have been shown to play an important role in regulation of β-cell proliferation (1,17,18). The Cip/Kip CKIs primarily inhibit Cdk2 but also have a role in assembling cdk4/cyclin D complex. Of the CKIs, p27Kip1 is thought to be the primary modulator of the proliferative status in most cell types, where it functions to induce and maintain the quiescent state (13,19,20). Recent studies showed that p27 deficiency prevented the development of overt hyperglycemia in both Irs2−/− and Lepr−/− mice by increased islet mass and serum insulin concentration (12). Our studies extend these data to the β-cell phenotype of p27-deficient mice in physiological conditions. In contrast to a previous report (21), our data showed that these mice have improved glucose tolerance. This is most likely the result of different genetic backgrounds of the mice and a lower glucose dose (1 mg/g) used for the glucose tolerance test. Our findings imply that the improved glucose tolerance results from increased β-cell mass and proliferation. Since these mice lack p27 during development, it is unclear if the major effect of p27 in regulation of β-cell mass and proliferation occurs early during pancreas development or if there is an effect of this CKI in driving cell cycle entry in mature β-cells. This could explain the fact that a 30% increase in proliferation in p27-null mice results in a twofold change in β-cell mass. In contrast to the striking changes in β-cell mass in mice containing a mutated cdk4 that is resistant to inhibition by p16, the phenotype of p27-deficient mice is rather mild. These experiments suggest that p27 deficiency does not result in unrestricted cell cycle progression and as shown by Franklin et al. (17) and Karnik et al. (18); deficiency in other CKIs are necessary to induce islet hyperplasia.

Based on the observations by Uchida et al. (12) and our results obtained in the p27-deficient mice, it was reasonable to expect that overexpressing p27 in β-cells from adult mice would result in diabetes. Surprisingly, overexpression of p27 in 8-week-old mice for 18 weeks had no effect on glucose tolerance or β-cell mass. The lack of a phenotype when p27 was expressed in adult mice is most likely explained by the low rate of proliferation and minimal turnover of adult β-cells as reported recently (22). Taking into consideration that the reported half-life of adult β-cells is 40 days (23), we can assume that 18 weeks would be enough time to see a phenotype, although it is possible that overexpression of p27 for a longer period of time would lead to a detectable phenotype. Our experiments expressing p27 during embryonic stages and early postnatal life suggest that p27 is critical to achieve a final functional β-cell mass in adult mice and that p27 acts as a key brake for progression through cell cycle induced by mitogenic signals. These data also confirm that the proliferative wave during the early postnatal period is crucial for achieving a final β-cell mass. Finally, the restoration of glucose tolerance and β-cell mass after discontinuing doxycycline is another example of the regenerative potential of β-cells. Interestingly, the proliferative rate measured after achieving normoglycemia in mice in which doxycycline was discontinued for 4 weeks was intermediate between that of DT mice receiving doxycycline and ST control mice. A potential explanation for the intermediate proliferative rates observed after discontinuation of doxycycline is that these measurements were performed after achieving normoglycemia and normal β-cell mass. It is possible that higher proliferative rates would have been observed at earlier times during the recovery process. Less likely, it is interesting to speculate that neogenesis could have contributed to the recovery of β-cell mass.

The results of these genetic studies suggest that the use of inducible systems of CKIs could generate information that cannot be obtained by traditional transgenesis and suggest that CKIs can have diverse effects during the different stages necessary to achieve adult β-cell mass. Another important conclusion of these experiments is that the major effect of p27 in regulation of β-cell cycle in physiological conditions occurs only during embryogenesis and early postneonatal period. Our results imply that p27 is a major regulator of cell cycle in conditions that require expansion of β-cell mass and that this CKI could contribute to the abnormal adaptation of β-cells observed in type 2 diabetes. The lack of unrestricted proliferation in p27-deficient mice and the importance of this CKI in improving the adaptation to insulin resistance in genetic models make this molecule an attractive target for pharmacological modulation.

FIG. 1.

Assessment of carbohydrate metabolism in p27-deficient mice. A: Weight measurements in 6- to 7-month-old female mice containing two alleles (+/+), one allele (+/-), or deficient in p27 (-/-) (n = 6). Blood glucose concentrations (B) and insulin levels (C) in 6-h fasted female mice (n = 6). D: Intraperitoneal glucose tolerance tests were performed in 4-month-old female mice (n > 5). Data are presented as means ± SE (*P < 0.05) (n > 4).

FIG. 1.

Assessment of carbohydrate metabolism in p27-deficient mice. A: Weight measurements in 6- to 7-month-old female mice containing two alleles (+/+), one allele (+/-), or deficient in p27 (-/-) (n = 6). Blood glucose concentrations (B) and insulin levels (C) in 6-h fasted female mice (n = 6). D: Intraperitoneal glucose tolerance tests were performed in 4-month-old female mice (n > 5). Data are presented as means ± SE (*P < 0.05) (n > 4).

FIG. 2.

Determination of islet morphometry and proliferation in p27-deficient mice. A: Determination of β-cell mass in 6- to 7-month-old p27+/+ and p27−/− female mice (n = 5). B: Assessment of proliferation by BrdU incorporation in p27+/+ and p27−/− mice (n = 3). Data are presented as means ± SE (*P < 0.05).

FIG. 2.

Determination of islet morphometry and proliferation in p27-deficient mice. A: Determination of β-cell mass in 6- to 7-month-old p27+/+ and p27−/− female mice (n = 5). B: Assessment of proliferation by BrdU incorporation in p27+/+ and p27−/− mice (n = 3). Data are presented as means ± SE (*P < 0.05).

FIG. 3.

Overexpression of p27 in β-cells from adult mice using a doxycycline-inducible model. A: Immunoblotting for p27 in islets from RIP7-rtTA or tetOp27Kip (ST) and RIP7-rtTA/tetOp27Kip (DT) mice chronically receiving doxycycline. B: Quantitation of band intensities for p27 and tubulin in islets from DT and ST mice chronically receiving doxycycline (n = 3). C: Six-hour fasting glucose measurements obtained from RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip (DT) mice. D: Insulin levels in 6-h fasted ST and DT mice. E: Intraperitoneal glucose tolerance tests after overnight fasting in ST and DT mice before initiation of doxycycline (dox) treatment. F: Intraperitoneal glucose tolerance tests performed in ST and DT mice after 16 weeks of doxycycline treatment. Data are presented as means ± SE (n > 8). *P < 0.05.

FIG. 3.

Overexpression of p27 in β-cells from adult mice using a doxycycline-inducible model. A: Immunoblotting for p27 in islets from RIP7-rtTA or tetOp27Kip (ST) and RIP7-rtTA/tetOp27Kip (DT) mice chronically receiving doxycycline. B: Quantitation of band intensities for p27 and tubulin in islets from DT and ST mice chronically receiving doxycycline (n = 3). C: Six-hour fasting glucose measurements obtained from RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip (DT) mice. D: Insulin levels in 6-h fasted ST and DT mice. E: Intraperitoneal glucose tolerance tests after overnight fasting in ST and DT mice before initiation of doxycycline (dox) treatment. F: Intraperitoneal glucose tolerance tests performed in ST and DT mice after 16 weeks of doxycycline treatment. Data are presented as means ± SE (n > 8). *P < 0.05.

FIG. 4.

Assessment of β-cell mass and proliferation in mice with overexpression of p27 in β-cells from adult mice. A: β-Cell mass measurements in RIP7-rtTA (WT), tetOp27Kip (ST), and double-transgenic RIP7-rtTA/tetOp27Kip (DT) mice after 18 weeks on doxycycline treatment. B: Assessment of β-cell proliferation by double staining for insulin and Ki67. Data are presented as means ± SE (n > 4) *P < 0.05.

FIG. 4.

Assessment of β-cell mass and proliferation in mice with overexpression of p27 in β-cells from adult mice. A: β-Cell mass measurements in RIP7-rtTA (WT), tetOp27Kip (ST), and double-transgenic RIP7-rtTA/tetOp27Kip (DT) mice after 18 weeks on doxycycline treatment. B: Assessment of β-cell proliferation by double staining for insulin and Ki67. Data are presented as means ± SE (n > 4) *P < 0.05.

FIG. 5.

Glucose homeostasis, β-cell mass, and proliferative rate in mice with overexpression of p27 during β-cell development and 8 weeks after birth. Six-hour fasted glucose measurements (A) and insulin values (B) in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT) after treatment with doxycycline during β-cell development and 4 weeks after birth. C: Intraperitoneal glucose tolerance tests in ST and DT mice that received doxycycline during β-cell development and 4 (C) and 8 (D) weeks after birth. E: β-Cell mass and proliferation rate assessed by Ki67 staining (F) in ST and DT mice that received doxycycline treatment during β-cell development and 8 weeks after birth. The data are presented as means ± SE (n > 6). *P < 0.05, **P < 0.01.

FIG. 5.

Glucose homeostasis, β-cell mass, and proliferative rate in mice with overexpression of p27 during β-cell development and 8 weeks after birth. Six-hour fasted glucose measurements (A) and insulin values (B) in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT) after treatment with doxycycline during β-cell development and 4 weeks after birth. C: Intraperitoneal glucose tolerance tests in ST and DT mice that received doxycycline during β-cell development and 4 (C) and 8 (D) weeks after birth. E: β-Cell mass and proliferation rate assessed by Ki67 staining (F) in ST and DT mice that received doxycycline treatment during β-cell development and 8 weeks after birth. The data are presented as means ± SE (n > 6). *P < 0.05, **P < 0.01.

FIG. 6.

Fasting glucose and glucose tolerance in mice with overexpression of p27 for 3 and 8 weeks after birth. A: Six-hour fasted glucose measurements in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT) after treatment with doxycycline for 3 weeks after birth. B and C: Intraperitoneal glucose tolerance tests in ST and DT mice that received doxycycline for 3 (B) and 8 (C) weeks after birth. The data are presented as means ± SE (n > 6). *P < 0.05, **P < 0.01.

FIG. 6.

Fasting glucose and glucose tolerance in mice with overexpression of p27 for 3 and 8 weeks after birth. A: Six-hour fasted glucose measurements in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT) after treatment with doxycycline for 3 weeks after birth. B and C: Intraperitoneal glucose tolerance tests in ST and DT mice that received doxycycline for 3 (B) and 8 (C) weeks after birth. The data are presented as means ± SE (n > 6). *P < 0.05, **P < 0.01.

FIG. 7.

Reversibility of glucose intolerance induced by overexpression of p27 during β-cell development and 4 weeks after birth. Six-hour fasted glucose measurements (A) and intraperitoneal glucose tolerance test (B) in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT+DOX) after treatment with doxycycline during β-cell development and 4 weeks after birth. Six-hour fasted glucose measurements (C) and intraperitoneal glucose tolerance test (D) in ST, DT+DOX (received doxycycline during development and 6 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 2 weeks) mice. Six-hour fasting glucose (E) and intraperitoneal glucose tolerance tests (F) in ST, DT+DOX (received doxycycline during development and 7 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 3 weeks) mice. Six-hour fasting glucose (G) and intraperitoneal glucose tolerance tests (H) in ST, DT+DOX (received doxycycline during development and 8 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 4 weeks) mice. *P < 0.05, **P < 0.01, ST compared with DT+DOX mice; #P < 0.05, ST compared with DT-DOX mice (n > 4).

FIG. 7.

Reversibility of glucose intolerance induced by overexpression of p27 during β-cell development and 4 weeks after birth. Six-hour fasted glucose measurements (A) and intraperitoneal glucose tolerance test (B) in RIP7-rtTA or tetOp27Kip mice (ST) and double-transgenic RIP7-rtTA/tetOp27Kip mice (DT+DOX) after treatment with doxycycline during β-cell development and 4 weeks after birth. Six-hour fasted glucose measurements (C) and intraperitoneal glucose tolerance test (D) in ST, DT+DOX (received doxycycline during development and 6 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 2 weeks) mice. Six-hour fasting glucose (E) and intraperitoneal glucose tolerance tests (F) in ST, DT+DOX (received doxycycline during development and 7 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 3 weeks) mice. Six-hour fasting glucose (G) and intraperitoneal glucose tolerance tests (H) in ST, DT+DOX (received doxycycline during development and 8 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 4 weeks) mice. *P < 0.05, **P < 0.01, ST compared with DT+DOX mice; #P < 0.05, ST compared with DT-DOX mice (n > 4).

FIG. 8.

Assessment of β-cell mass and proliferation in ST, DT+DOX, and DT-DOX mice. A: Quantitation of β-cell mass in RIP7-rtTA or tetOp27Kip (ST), double-transgenic RIP7-rtTA/tetOp27Kip (DT+DOX; received doxycycline during development and 8 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 4 weeks) mice. B: β-Cell proliferation assessed by Ki67 staining in the same group of mice. The data are presented as means ± SE (n > 4). *P < 0.05, **P < 0.01.

FIG. 8.

Assessment of β-cell mass and proliferation in ST, DT+DOX, and DT-DOX mice. A: Quantitation of β-cell mass in RIP7-rtTA or tetOp27Kip (ST), double-transgenic RIP7-rtTA/tetOp27Kip (DT+DOX; received doxycycline during development and 8 weeks after birth), and DT-DOX (received doxycycline during β-cell development and 4 weeks after birth, followed by discontinuation of doxycycline for 4 weeks) mice. B: β-Cell proliferation assessed by Ki67 staining in the same group of mice. The data are presented as means ± SE (n > 4). *P < 0.05, **P < 0.01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work was supported in part by a Junior Faculty Award and Career Development Award from the American Diabetes Association (to E.B.-M.).

The authors acknowledge the support of the Washington University Diabetes Research and Training Center for insulin measurements and histology and the Washington University Digestive Diseases Research Core Center grant morphology core.

1.
Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.
Nat Genet
22
:
44
–52,
1999
2.
Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H: Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.
Mol Cell Biol
19
:
7011
–7019,
1999
3.
Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
Cell
118
:
493
–504,
2004
4.
Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, White MF: Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth.
Mol Cell Biol
25
:
3752
–3762,
2005
5.
Cozar-Castellano I, Takane KK, Bottino R, Balamurugan AN, Stewart AF: Induction of β-cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenovirus-mediated transfer of cyclin-dependent kinase-4 and cyclin D1.
Diabetes
53
:
149
–159,
2004
6.
Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, Takane KK, Garcia-Ocana A, Vasavada R, Stewart AF: Molecular control of cell cycle progression in the pancreatic beta-cell.
Endocr Rev
27
:
356
–370,
2006
7.
Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).
Mol Cell Biol
20
:
9138
–9148,
2000
8.
Servant MJ, Coulombe P, Turgeon B, Meloche S: Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms.
J Cell Biol
148
:
543
–556,
2000
9.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.
Nat Med
8
:
1153
–1160,
2002
10.
Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Nat Med
8
:
1136
–1144,
2002
11.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Nat Med
8
:
1145
–1152,
2002
12.
Uchida T, Nakamura T, Hashimoto N, Matsuda T, Kotani K, Sakaue H, Kido Y, Hayashi Y, Nakayama KI, White MF, Kasuga M: Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice.
Nat Med
11
:
175
–182,
2005
13.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).
Cell
85
:
721
–732,
1996
14.
Milo-Landesman D, Surana M, Berkovich I, Compagni A, Christofori G, Fleischer N, Efrat S: Correction of hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet-on regulatory system.
Cell Transplant
10
:
645
–650,
2001
15.
Bernal-Mizrachi E, Cras-Meneur C, Ohsugi M, Permutt MA: Gene expression profiling in islet biology and diabetes research.
Diabetes Metab Res Rev
19
:
32
–42,
2003
16.
Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA: Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia.
J Clin Invest
108
:
1631
–1638,
2001
17.
Franklin DS, Godfrey VL, O’Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.
Mol Cell Biol
20
:
6147
–6158,
2000
18.
Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
Proc Natl Acad Sci U S A
102
:
14659
–14664,
2005
19.
Rivard N, L’Allemain G, Bartek J, Pouyssegur J: Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts.
J Biol Chem
271
:
18337
–18341,
1996
20.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.
Cell
85
:
707
–720,
1996
21.
Naaz A, Holsberger DR, Iwamoto GA, Nelson A, Kiyokawa H, Cooke PS: Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
FASEB J
18
:
1925
–1927,
2004
22.
Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA: Very slow turnover of β-cells in aged adult mice.
Diabetes
54
:
2557
–2567,
2005
23.
Finegood DT, Scaglia L, Bonner-Weir S: Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model.
Diabetes
44
:
249
–256,
1995